Tetsuya Tsukamoto
Overview
Explore the profile of Tetsuya Tsukamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
216
Citations
2639
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cui Y, Cao X, Zhang Y, Fu C, Li D, Sun Y, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):52.
PMID: 39948597
Background: Glucose metabolism plays a critical role in tumor progression. When glucose intake is insufficient and the tumor's growth rate exceeds its energy supply, tumor cells typically adapt and overcome...
2.
Teramoto A, Michiba A, Kiriyama Y, Tsukamoto T, Imaizumi K, Fujita H
Cytopathology
. 2025 Feb;
PMID: 39918342
Objective: Cytology plays a crucial role in lung cancer diagnosis. Pulmonary cytology involves cell morphological characterisation in the specimen and reporting the corresponding findings, which are extremely burdensome tasks. In...
3.
Wei R, Song J, Liu C, Zhao Z, Liu X, Yamamoto M, et al.
Cancer Lett
. 2025 Jan;
612:217475.
PMID: 39828123
FAP-positive cancer-associated fibroblasts (CAFs), recognized as a critical subset of CAFs, have been implicated in fostering an immunosuppressive tumor microenvironment in various cancers. However, their potential mechanisms of immunosuppression, particularly...
4.
Tsutsumi C, Ohuchida K, Tsutsumi H, Shimada Y, Yamada Y, Son K, et al.
Cancer Lett
. 2024 Dec;
611:217412.
PMID: 39722406
Therapies targeting HER2 are the standard treatment for HER2-positive gastric cancer (GC). Trastuzumab, a monoclonal antibody against HER2, exerts anti-tumor activity through cell growth regulation and antibody-dependent cellular cytotoxicity (ADCC)....
5.
Yamada S, Satou A, Tsuyuki Y, Iba S, Okumura Y, Ishikawa E, et al.
Pathol Int
. 2024 Dec;
75(1):11-20.
PMID: 39660959
CD5 expression is seen in 5%-10% of de novo diffuse large B-cell lymphomas (DLBCLs). Primary large B-cell lymphoma of the central nervous system (PCNS-LBCL) also exhibits CD5 expression in a...
6.
Su R, Sun X, Luo Y, Gu L, Wang F, Dong A, et al.
Gastric Cancer
. 2024 Dec;
28(2):245-263.
PMID: 39656339
Background: The expression patterns and functions of Sushi Domain Containing 2 (SUSD2) differ among various malignancies. This research aims to investigate the expression of SUSD2 and the role of the...
7.
Takahashi T, Ozawa Y, Hattori H, Nomura M, Ueda T, Horiguchi T, et al.
J Thorac Imaging
. 2024 Sep;
39(6):W96-W99.
PMID: 39279292
No abstract available.
8.
Kawasaki R, Kukimoto I, Tsukamoto T, Nishio E, Iwata A, Fujii T
Cancer Sci
. 2024 Aug;
115(11):3672-3681.
PMID: 39171738
Approximately 660,000 women are diagnosed with cervical cancer annually. Current screening options such as cytology or human papillomavirus testing have limitations, creating a need to identify more effective ancillary biomarkers...
9.
Capuano A, Vescovo M, Canesi S, Pivetta E, Doliana R, Nadin M, et al.
Gastric Cancer
. 2024 Jun;
27(5):1016-1030.
PMID: 38941035
Background: The contribution of the tumor microenvironment and extracellular matrix to the aggressive biology of Gastric Cancer (GC) has been recently characterized; however, the role of EMILIN-1 in this context...
10.
Jiang Y, Wang Y, Chen G, Sun F, Wu Q, Huang Q, et al.
Cell Metab
. 2024 Jun;
36(8):1806-1822.e11.
PMID: 38897198
Immune checkpoint blockade has led to breakthroughs in the treatment of advanced gastric cancer. However, the prominent heterogeneity in gastric cancer, notably the heterogeneity of the tumor microenvironment, highlights the...